Expertise in
5
conditions

Dr. Rangaswamy K. Govindarajan

Hematology
Uams Sats Program
4301 W Markham St, 
Little Rock, AR 
Accepting New Patients
Expertise in
5
conditions
Uams Sats Program
4301 W Markham St, 
Little Rock, AR 

Overview

Rangaswamy Govindarajan is a Hematologist practicing medicine in Little Rock, Arkansas.

Dr. Govindarajan is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Squamous Cell Carcinoma of the Anal Canal (SCAC), Gallbladder Adenocarcinoma, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Gastrostomy.

He is actively involved in clinical research, co-authoring 15 peer reviewed articles and participating in 20 clinical trials. Dr. Govindarajan is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in AR

Hospital Affiliations

University Of Arkansas Medical Sciences

Languages Spoken

English
Arabic

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Arkansas Health and Wellness
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
HMO Partners
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
QualChoice
  • MEDICARE MAPD
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Uams Sats Program
4301 W Markham St, Little Rock, AR 72205
Other Locations
Office
4018 W Capitol Ave, Little Rock, AR 72205

Additional Areas of Focus

Dr. Govindarajan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Carboplatin, Cetuximab
Study Phase: Phase 2
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2026
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2026
Intervention Type: Procedure
View 9 Less Clinical Trials

15 Total Publications

A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence.
A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence.
Journal: Oncotarget
Published: June 06, 2026
Similar Doctors
Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Uams Sats Program

4301 W Markham St, 
Little Rock, AR 
 (0.1 miles away)
501-686-8230
Languages Spoken:
English, Italian
See accepted insurances
Accepting New Patients
Offers Telehealth

Maurizio Zangari is a Hematologist practicing medicine in Little Rock, Arkansas. Dr. Zangari is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Zangari is currently accepting new patients.

Expertise in
9
conditions
Dr. Sharmilan Thanendrarajan
Hematology | Oncology
Expertise in
9
conditions
Dr. Sharmilan Thanendrarajan
Hematology | Oncology
Referral may be required

Uams Sats Program

4301 W Markham St, 
Little Rock, AR 
 (0.1 miles away)
501-526-6990
Languages Spoken:
English, German
See accepted insurances
Offers Telehealth

Sharmilan Thanendrarajan is a Hematologist and an Oncologist practicing medicine in Little Rock, Arkansas. Dr. Thanendrarajan is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

Uams Sats Program

4301 W Markham St, 
Little Rock, AR 
 (0.1 miles away)
501-526-2873
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Carolina Schinke is a Hematologist practicing medicine in Little Rock, Arkansas. Dr. Schinke is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Transplant. Dr. Schinke is currently accepting new patients.

Frequently Asked Questions about Dr. Rangaswamy K. Govindarajan

How do I make an appointment with Dr. Rangaswamy K. Govindarajan?

You can book an appointment with Dr. Rangaswamy K. Govindarajan by calling their office at 501-686-8511. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rangaswamy K. Govindarajan a top-rated expert for Squamous Cell Carcinoma of the Anal Canal (SCAC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rangaswamy K. Govindarajan is classified as an Distinguished expert for Squamous Cell Carcinoma of the Anal Canal (SCAC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rangaswamy K. Govindarajan specialize in?

While Dr. Rangaswamy K. Govindarajan is a Hematology, they have specific expertise in Squamous Cell Carcinoma of the Anal Canal (SCAC), Gallbladder Adenocarcinoma, and Myelodysplastic Syndrome (MDS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Rangaswamy K. Govindarajan participate in research or clinical trials?

Yes. Dr. Rangaswamy K. Govindarajan has published 15 articles and abstracts on conditions like Squamous Cell Carcinoma of the Anal Canal (SCAC). You can view a list of Dr. Rangaswamy K. Govindarajan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rangaswamy K. Govindarajan accept my insurance?

Dr. Rangaswamy K. Govindarajan accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 501-686-8511 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Govindarajan's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile